118468-18-1Relevant articles and documents
A novel quinazoline-based analog induces G2/M cell cycle arrest and apoptosis in human A549 lung cancer cells via a ROS-dependent mechanism
Shi, Hailong,Li, Yan,Ren, Xiaorong,Zhang, Yaohong,Yang, Zhen,Qi, Chenze
, p. 314 - 320 (2017)
6-amino-4-(4-phenoxyphenylethylamino)quinazoline (QNZ) is an excellent quinazoline-containing NF-κB inhibitor also acting as a novel anticancer agent. Considering both the medicinal significance of quinazoline scaffold and the tunable functionality of Mic
6-amino-4-(4-phenoxyphenylethylamino)quinazoline derivative as well as preparation method and application thereof
-
Paragraph 0036; 0041-0042, (2021/01/24)
The invention belongs to the technical field of medicines, and particularly relates to a 6-amino-4-(4-phenoxyphenylethylamino)quinazoline (QNZ) derivative as well as a preparation method and application thereof. According to the invention, a series of QNZ
Inhibitors of protein farnesyltransferase and squalene synthase
-
, (2008/06/13)
The present invention provides a compound of the formula STR1 or a pharmaceutically acceptable salt thereof, which are useful in inhibiting protein farnesyltransferase and the farnesylation of the oncogene protein Ras or inhibiting de novo squalene production resulting in the inhibition of cholesterol biosynthesis, processes for the preparation of the compounds of the invention in addition to intermediates useful in these processes, a pharmaceutical composition, and to methods of using such compounds.
